SCHEMBL1367959

SCHEMBL1367959

N#Cc1nc(Cl)c2ccccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 5/20 0.52
MAOA P21397 2/20 0.47
MAOB P27338 1/20 0.47
METAP1 P53582 1/20 0.45
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
NSD2 O96028 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 3/20 0.39
POLB P06746 2/20 0.39
GLA P06280 2/20 0.39
HPGD P15428 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22694401 0.77 ADORA2A (0.56) KDM4EALDH1A1MAPTGLAHPGD
SCHEMBL19169958 0.77 GPR3 (0.53) KDM4EALDH1A1NSD2SMN1; SMN2MAPT
SCHEMBL28357536 0.74 MAOA (0.52) KDM4EALDH1A1MAOAMAOBMETAP1
SCHEMBL19170128 0.73 KDM4E (0.47) KDM4EALDH1A1MAOAMAOBTDP1
SCHEMBL21085719 0.73 KDM4E (0.47) KDM4EALDH1A1NSD2SMN1; SMN2MAPT
SCHEMBL14493452 0.73 ALDH1A1 (0.47) KDM4EALDH1A1MAOAMAOBTDP1
SCHEMBL786440 0.73 METAP1 (0.53) KDM4EALDH1A1MAOAMAOBMETAP1
SCHEMBL29389300 0.73 MAOA (0.56) KDM4EALDH1A1MAOAMAOBMETAP1
SCHEMBL92707 0.73 MAOA (0.56) KDM4EALDH1A1MAOAMAOBMETAP1
SCHEMBL29799045 0.72 ALDH1A1 (0.60) KDM4EALDH1A1MAOAMAOBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530652-B2 Pyrrolopyrazoles, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2013-09-10 US disclosed
US-20120264751-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS AGOURON PHARMACEUTICALS, INC. 2012-10-18 US disclosed
US-8067591-B2 Pyrrolopyrazole, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-8067591-B2 Pyrrolopyrazole, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-8067591-B2 Pyrrolopyrazole, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
EP-1838718-B1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PFIZER (US) 2011-06-15 EP disclosed
EP-1838718-B1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PFIZER (US) 2011-06-15 EP disclosed
CN-101115760-B Pyrrolopyrazoles, potent kinase inhibitors PFIZER 2010-11-03 CN disclosed
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS ZHANG JUNHU 2010-09-02 US disclosed
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS ZHANG JUNHU 2010-09-02 US disclosed
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS ZHANG JUNHU 2010-09-02 US disclosed
CN-101115760-A Pyrrolopyrazoles, potent kinase inhibitors PFIZER (US) 2008-01-30 CN disclosed
EP-1838718-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS Pfizer, Inc. (US) 2007-10-03 EP disclosed
WO-2006072831-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PFIZER INC. (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264751-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PAK4, PAK5, PAK3 KDM4E 1102/4885ALDH1A1 2941/4885MAOA 3865/4885
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS PAK4, PAK5, PAK3 KDM4E 1294/4885ALDH1A1 3130/4885MAOA 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.